Abstract
Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is involved in cell proliferation, growth, migration, invasion and survival, and has been found to be overexpressed in non-small-cell lung cancer. Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. In elderly patients, with a poor prognosis, and different co-morbidities, erlotinib and gefitinib could be considered as valid therapeutic options. This paper reviews the role of both drugs, in the management of elderly patients affected by advanced NSCLC based on an update analysis of randomised and non-randomised clinical trials.
Keywords: EGFR, elderly, erlotinib, gefitinib, non-small-cell lung cancer, tyrosine kinase inhibitor.
Anti-Cancer Agents in Medicinal Chemistry
Title:Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
Volume: 14 Issue: 5
Author(s): Antonio Passaro, Daniele Alesini, Alessia Pochesci and Enrico Cortesi
Affiliation:
Keywords: EGFR, elderly, erlotinib, gefitinib, non-small-cell lung cancer, tyrosine kinase inhibitor.
Abstract: Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is involved in cell proliferation, growth, migration, invasion and survival, and has been found to be overexpressed in non-small-cell lung cancer. Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. In elderly patients, with a poor prognosis, and different co-morbidities, erlotinib and gefitinib could be considered as valid therapeutic options. This paper reviews the role of both drugs, in the management of elderly patients affected by advanced NSCLC based on an update analysis of randomised and non-randomised clinical trials.
Export Options
About this article
Cite this article as:
Passaro Antonio, Alesini Daniele, Pochesci Alessia and Cortesi Enrico, Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (5) . https://dx.doi.org/10.2174/187152061405140501101624
DOI https://dx.doi.org/10.2174/187152061405140501101624 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Quality Retention and Shelf-life Improvement of Fresh-cut Apple, Papaya, Carrot and Cucumber by Chitosan-soy Based Edible Coating
Current Nutrition & Food Science Treatment of Elderly Patients Affected by Lung Cancer: Why to Treat, when to Treat and what we Know
Anti-Cancer Agents in Medicinal Chemistry Galanthus nivalis Agglutinin (GNA)-Related Lectins: Traditional Proteins, Burgeoning Drugs?
Current Chemical Biology Autoantibody Profiles as Biomarkers for Response to Therapy and Early Detection of Cancer
Current Cancer Therapy Reviews Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Current Cancer Drug Targets Antibody-Based Preventive and Therapeutic Strategies Against HIV
Current HIV Research The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology Thiopurines in Inflammatory Bowel Disease - The Role of Pharmacogenetics and Therapeutic Drug Monitoring
Current Pharmacogenomics Single-cell RNA Sequencing Analysis Identifies Key Genes in Brain Metastasis from Lung Adenocarcinoma
Current Gene Therapy Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Editorial
Current Cancer Therapy Reviews Recent Advances of Metallocenes for Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Is Fast Food Addictive?
Current Drug Abuse Reviews High Order Texture-Based Analysis in Biomedical Images
Current Medical Imaging